MRS2 and endometrial cancer: A 5-biomarker signature of cervico-vaginal fluid proteins combining HPT, LG3BP, FGA, LY6D and IGHM predicted endometrial cancer with an AUC of 0.95 (0.91–0.98), sensitivity of 91%, and specificity of 86%.